In summary, we have determined that cetuximab-IONPs bind to both the wtEGFR and the EGFRvIII deletion mutant on human patient-derived GBM cells (including GSCs), inhibit EGFR cell signaling, are internalized by the tumor cells, and promote internalization of the EGFR resulting in enhanced apoptosis. Here, EGFR is linked to neoplasm.